rs80359432
Positions:
Variant summary
Our verdict is Benign. Variant got -7 ACMG points: 1P and 8B. PM4_SupportingBP6_Very_Strong
The NM_000059.4(BRCA2):c.4146_4148del(p.Glu1382del) variant causes a inframe deletion change. The variant allele was found at a frequency of 0.000122 in 1,609,136 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Benign (★★★). Synonymous variant affecting the same amino acid position (i.e. K1381K) has been classified as Likely benign.
Frequency
Genomes: 𝑓 0.000053 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00013 ( 0 hom. )
Consequence
BRCA2
NM_000059.4 inframe_deletion
NM_000059.4 inframe_deletion
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 5.11
Genes affected
BRCA2 (HGNC:1101): (BRCA2 DNA repair associated) Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11, which harbors the most important and frequent mutations in breast cancer patients. The BRCA2 gene was found on chromosome 13q12.3 in human. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, May 2020]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -7 ACMG points.
PM4
Nonframeshift variant in NON repetitive region in NM_000059.4. Strenght limited to Supporting due to length of the change: 1aa.
BP6
Variant 13-32338496-AAAG-A is Benign according to our data. Variant chr13-32338496-AAAG-A is described in ClinVar as [Benign]. Clinvar id is 37883.Status of the report is reviewed_by_expert_panel, 3 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
BRCA2 | NM_000059.4 | c.4146_4148del | p.Glu1382del | inframe_deletion | 11/27 | ENST00000380152.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
BRCA2 | ENST00000380152.8 | c.4146_4148del | p.Glu1382del | inframe_deletion | 11/27 | 5 | NM_000059.4 | A2 |
Frequencies
GnomAD3 genomes AF: 0.0000526 AC: 8AN: 152202Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
8
AN:
152202
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000733 AC: 18AN: 245496Hom.: 0 AF XY: 0.0000754 AC XY: 10AN XY: 132570
GnomAD3 exomes
AF:
AC:
18
AN:
245496
Hom.:
AF XY:
AC XY:
10
AN XY:
132570
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000130 AC: 189AN: 1456934Hom.: 0 AF XY: 0.000139 AC XY: 101AN XY: 724372
GnomAD4 exome
AF:
AC:
189
AN:
1456934
Hom.:
AF XY:
AC XY:
101
AN XY:
724372
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000526 AC: 8AN: 152202Hom.: 0 Cov.: 33 AF XY: 0.0000672 AC XY: 5AN XY: 74368
GnomAD4 genome
AF:
AC:
8
AN:
152202
Hom.:
Cov.:
33
AF XY:
AC XY:
5
AN XY:
74368
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Benign
Submissions summary: Uncertain:8Benign:11
Revision: reviewed by expert panel
LINK: link
Submissions by phenotype
not specified Uncertain:2Benign:3
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | May 02, 2019 | The BRCA2 c.4146_4148delAGA; p.Glu1382del variant (rs80359432) is reported in the literature in several individuals affected with breast cancer (Dodova 2015, Monnerat 2007), although a pathogenic variant in TP53 was also found in one affected individual (Monnerat 2007). This variant is found in the general population with an overall allele frequency of 0.007% (20/276904 alleles) in the Genome Aggregation Database, and it is reported in ClinVar (Variation ID: 37883). This variant deletes a single glutamate residue, leaving the rest of the protein in-frame. In functional assays, this variant exhibits decreased ability to promote cell survival and homology-directed repair, though it does not induce centrosome amplification (Wu 2005). However, due to limited clinical data, the significance of the p.Glu1382del variant is uncertain at this time. References: Dodova RI et al. Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients. BMC Cancer. 2015 Jul 17;15:523. Monnerat C et al. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma. Fam Cancer. 2007;6(4):453-61. Wu K et al. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res. 2005 Jan 15;65(2):417-26. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 28, 2016 | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Clinvar: 3 labs classify as LB, 1 as VUS; ExAC: 2/6606 European chromosomes - |
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 09, 2023 | Variant summary: BRCA2 c.4146_4148delAGA (p.Glu1382del) results in an in-frame deletion that is predicted to remove one amino acid from the encoded protein. A recent report from the CAGI5 (fifth Critical Assessment of Genome Interpretation) challenge has classified this variant as benign (class 1) in a prediction protocol that includes assessment of the impact of this variant on splicing and protein function using four sets of predictors (Padilla_2019). The variant allele was found at a frequency of 7.3e-05 in 246448 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in BRCA2 causing Hereditary Breast And Ovarian Cancer Syndrome (7.3e-05 vs 0.00075), allowing no conclusion about variant significance. c.4146_4148delAGA has been reported in the literature in individuals affected with Breast and Ovarian Cancer (example, Wu_2005, Bosdet_2013, Monnerat_2007, Dodova_2015, Pharoah_2000). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. At-least two co-occurrences with other pathogenic variant(s) have been reported in the UMD database and at our laboratory (UMD database, BRCA1 c.4162_4163delCA, p.Gln1388GlufsX2; Our laboratory, BRIP1 c.2010dupT , p.Glu671Ter), providing supporting evidence for a benign role. At least one publication reports experimental evidence evaluating an impact on protein function (Wu_2005). The most pronounced variant effect results in conflicting evidence between HDR activity (supportive of loss), nuclear localization (normal), sensitivity to mitomycin C (MMC, supportive of loss), and centrosome number (normal) with the authors concluding that functional effects alone should not be taken as definite proof for pathogenicity as there is lacking information about cosegregation and limited patient reports. Multiple clinical diagnostic laboratories and an expert panel (ENIGMA) have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple submitters reported the variant with conflicting assessments (Benign, n=3 to include the expert panel; likely benign, n=3; VUS, n=5). Some submitters cite overlapping evidence utilized in the context of this evaluation. Based on the evidence outlined above supported by an emerging majority consensus among peers and the expert panel, the variant was classified as likely benign. - |
Benign, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Benign, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Feb 06, 2024 | - - |
Breast-ovarian cancer, familial, susceptibility to, 2 Uncertain:2Benign:3
Benign, reviewed by expert panel | curation | Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) | Jun 18, 2019 | IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 1 based on posterior probability = 1.46E-06 - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Sep 11, 2016 | - - |
Benign, no assertion criteria provided | clinical testing | BRCAlab, Lund University | Mar 02, 2020 | - - |
Likely benign, no assertion criteria provided | clinical testing | Sharing Clinical Reports Project (SCRP) | Sep 24, 2008 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Breast Cancer Information Core (BIC) (BRCA2) | Feb 20, 2004 | - - |
not provided Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Jun 02, 2023 | In the published literature, this variant has been reported in individuals with breast cancer (PMID: 26183948 (2015), 17624602 (2007), and 11044354 (2000)). Functional studies have reported that this variant may have deleterious effects on BRCA2 protein function, however further studies are needed to determine the global effect of this variant on BRCA2 protein activity (PMID: 15695382 (2005)). The frequency of this variant in the general population, 0.000078 (10/127472 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Based on the available information, we are unable to determine the clinical significance of this variant. - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | May 09, 2018 | This variant is associated with the following publications: (PMID: 24094589, 26543556, 19941162, 15695382, 17624602, 26183948, 11044354, 24323938) - |
Hereditary cancer-predisposing syndrome Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 25, 2019 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Oct 01, 2015 | - - |
Hereditary breast ovarian cancer syndrome Benign:2
Benign, criteria provided, single submitter | clinical testing | National Health Laboratory Service, Universitas Academic Hospital and University of the Free State | Apr 19, 2022 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Invitae | Jan 18, 2024 | - - |
Breast and/or ovarian cancer Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | May 14, 2020 | - - |
BRCA2-related disorder Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 09, 2023 | The BRCA2 c.4146_4148delAGA variant is predicted to result in an in-frame deletion (p.Glu1382del). This variant has been reported to impair homology directed repair and exhibit hypersensitivity to mitomycin C, but did not alter centrosome amplification using in vitro assays (Guidugli L et al 2013. PubMed ID: 24323938). The c.4146_4148del variant has been reported a limited number of cases of breast cancer (Monnerat et al. 2007. PubMed ID: 17624602; Dodova RI et al 2015. PubMed ID: 26183948). This variant is reported in 0.024% of alleles in individuals of European (Finnish) descent in gnomAD and has been interpreted as uncertain, likely benign, and benign in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/37883/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Malignant tumor of breast Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The p.Glu1382del variant is an in-frame deletion resulting in the removal of a glutamic acid (Glu) residue at position 1382. This variant has been identified in the literature and was identified in the LOVD database, in the BIC database 5X as a variant of unknown clinical importance, and is listed in the dbSNP database (ID#: rs80359432) “with non-pathogenic allele”, however no frequency information was provided. The variant was also identified in the UMD database (1x as an "unknown variant") where it was reported as co-occurring with another pathogenic variant (BRCA1 c.4162_4163delCA (p.Gln1388GlufsX2)), increasing the likelihood that the p.Glu1382del variant does not have clinical significance. This residue is not conserved in mammals, with a different amino acid, glycine (Gly), present in opossum at this position. One functional study suggested that the variant specifically alters Rad51 binding by BRCA2, resulting in loss of DNA repair activity (Wu 2005). However, the results of other functional assays in this study, including evaluation of nuclear localization and centrosome number, were similar to wild type BRCA2 which suggests that the variant may not confer a conformational change on BRCA2 that leads to inactivation of all BRCA2 functions (Wu 2005). In summary, the clinical significance of this variant cannot be determined with certainty at this time. Therefore this variant is classified as a variant of unknown significance (VUS). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at